Genki Watanabe1, Yoshihiro Mise1, Hiromichi Ito1, Yosuke Inoue1, Takeaki Ishizawa1, Yu Takahashi1, Akio Saiura2. 1. Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. 2. Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. saiura-tky@umin.ac.jp.
Abstract
BACKGROUND: It is unclear how early liver recurrence negatively affects survival in patients undergoing surgery for colorectal liver metastases (CLM) and whether to perform re-hepatectomy for early recurrence is still controversial. We aimed to evaluate the prognostic value of re-hepatectomy for early recurrence of CLM. METHODS: We reviewed 634 patients undergoing initial hepatectomy for CLM between 2004 and 2015. In 131 patients (20.7%), liver recurrence occurred within 6 months after surgery (early recurrence group [ER]). Recurrence pattern and survivals of ER were compared with those of 150 patients (23.7%) who had liver recurrence more than 6 months after surgery (late recurrence group [LR]). Re-hepatectomy was indicated for resectable disease regardless of the timing of recurrence without using preoperative chemotherapy. RESULTS: The 5-year overall survival (OS) rates after initial hepatectomy in ER (24.0%) were worse than those in LR (57.7%, p < 0.01). Although the incidence of concomitant extrahepatic recurrence was not different between ER and LR, the rate of re-hepatectomy for recurrence confined to the liver in ER (72.5% [58/80]) was lower than that in LR (88.9% [96/108], p < 0.01). In ER, re-hepatectomy was found to independently improve survival (HR: 6.479, p < 0.01), offering the 5-year OS rate after re-hepatectomy of 45.2%. The sites and timing of re-recurrence after re-hepatectomy were not different between ER and LR. CONCLUSIONS: Impaired survival of early liver recurrence is attributed to extensive liver recurrence. However, re-hepatectomy indicated based on resectability is associated with improved survival in patients with early recurrence, tempering the re-recurrence mode.
BACKGROUND: It is unclear how early liver recurrence negatively affects survival in patients undergoing surgery for colorectal liver metastases (CLM) and whether to perform re-hepatectomy for early recurrence is still controversial. We aimed to evaluate the prognostic value of re-hepatectomy for early recurrence of CLM. METHODS: We reviewed 634 patients undergoing initial hepatectomy for CLM between 2004 and 2015. In 131 patients (20.7%), liver recurrence occurred within 6 months after surgery (early recurrence group [ER]). Recurrence pattern and survivals of ER were compared with those of 150 patients (23.7%) who had liver recurrence more than 6 months after surgery (late recurrence group [LR]). Re-hepatectomy was indicated for resectable disease regardless of the timing of recurrence without using preoperative chemotherapy. RESULTS: The 5-year overall survival (OS) rates after initial hepatectomy in ER (24.0%) were worse than those in LR (57.7%, p < 0.01). Although the incidence of concomitant extrahepatic recurrence was not different between ER and LR, the rate of re-hepatectomy for recurrence confined to the liver in ER (72.5% [58/80]) was lower than that in LR (88.9% [96/108], p < 0.01). In ER, re-hepatectomy was found to independently improve survival (HR: 6.479, p < 0.01), offering the 5-year OS rate after re-hepatectomy of 45.2%. The sites and timing of re-recurrence after re-hepatectomy were not different between ER and LR. CONCLUSIONS: Impaired survival of early liver recurrence is attributed to extensive liver recurrence. However, re-hepatectomy indicated based on resectability is associated with improved survival in patients with early recurrence, tempering the re-recurrence mode.
Authors: Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Antoine Brouquet; Michael J Overman; Scott Kopetz; Dipen M Maru; Evelyne M Loyer; Andreas Andreou; Amanda Cooper; Steven A Curley; Christopher R Garrett; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: Cancer Date: 2011-03-28 Impact factor: 6.860
Authors: D A Wicherts; R J de Haas; C Salloum; P Andreani; G Pascal; D Sotirov; R Adam; D Castaing; D Azoulay Journal: Br J Surg Date: 2013-03-12 Impact factor: 6.939
Authors: L J M Mekenkamp; M Koopman; S Teerenstra; J H J M van Krieken; L Mol; I D Nagtegaal; C J A Punt Journal: Br J Cancer Date: 2010-06-15 Impact factor: 7.640
Authors: George P Kim; Daniel J Sargent; Michelle R Mahoney; Kendrith M Rowland; Philip A Philip; Edith Mitchell; Abraham P Mathews; Tom R Fitch; Richard M Goldberg; Steven R Alberts; Henry C Pitot Journal: J Clin Oncol Date: 2009-04-20 Impact factor: 44.544
Authors: Emmanuel Mitry; Anthony L A Fields; Harry Bleiberg; Roberto Labianca; Guillaume Portier; Dongsheng Tu; Donato Nitti; Valter Torri; Dominique Elias; Chris O'Callaghan; Bernard Langer; Giancarlo Martignoni; Olivier Bouché; Franck Lazorthes; Eric Van Cutsem; Laurent Bedenne; Malcolm J Moore; Philippe Rougier Journal: J Clin Oncol Date: 2008-09-15 Impact factor: 44.544
Authors: Luca Viganò; Lorenzo Capussotti; Réal Lapointe; Eduardo Barroso; Catherine Hubert; Felice Giuliante; Jan N M Ijzermans; Darius F Mirza; Dominique Elias; René Adam Journal: Ann Surg Oncol Date: 2013-12-18 Impact factor: 5.344
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321